Vertex Pharmaceuticals’ Post

Our teams had the privilege of participating in the 52nd Annual European Society for Blood and Marrow Transplantation (EBMT) Meeting. It was an incredible opportunity to connect with our peers in this space as we work to bring hope to patients with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Learn more about our work in SCD and TDT: https://lnkd.in/ebztA3xN #EBMT26

  • No alternative text description for this image

These moments to connect and exchange perspectives across the community are so valuable, and can lead to a meaningful difference for patients.

Like
Reply

To view or add a comment, sign in

Explore content categories